Pfizer to raise prices on 41 drugs in 2019

Amy Baxter | | Health Exec | Policy & Regulations
Researchers found millions of heart failure patients who qualify for standard, guideline directed medical therapies, but did not receive it due to poor health literacy, limited access to care and medication costs.

Drug manufacturer Pfizer announced it would raise the prices of 41 drugs in January 2019, The Wall Street Journal reported. The move comes after the company committed to not raising prices in 2018 after coming under fire from President Trump. That commitment did not extend into 2019.

Most of the increases will be 5 percent, though one drug’s price will jump 9 percent, while three will only increase 3 percent, the WSJ reported. Most of the company’s portfolio of prescription drugs––90 percent––won’t be impacted by the price increases.

Rising drug prices have become a hot topic for the Trump administration, which has taken several steps to challenge the drug industry.

See the full story below:

Pfizer to Raise Prices on 41 Drugs in January

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

HHS sued over RFK’s $11B cuts to infectious disease control
FDA announces new recall of Abbott heart pump accessories over significant safety risks
Gov. DeSantis accused of diverting $10M in Medicaid funds to charity run by wife
FDA issues Class I recall on dangerous infusion bags
Atrial Fibrillation Centers of Excellence: The best path forward for high-quality care and better outcomes
Tariffs threaten imaging access for patients, RBMA warns

Around the web

Cardiovascular Business
FDA announces new recall of Abbott heart pump accessories over significant safety risks

The mobile power units of certain HeartMate 3 and HeartMate II LVADs have been experiencing “sudden, unexpected performance issues” such as turning on, off or even restarting with no warning. These issues can potentially be fatal, according to an alert shared by the FDA.

Radiology Business
Tariffs threaten imaging access for patients, RBMA warns

Radiology practices are already operating on razor thin margins, with price increases prompting calls for congressional action to prevent further damage. 

Radiology Business
Chinese radiology vendors dodge high tariffs with US-based factories

United Imaging and other manufacturers that have established American factories may remain insulated from the trade war.